Oxytocin, an OXTR agonist marketed under the trade name OXYTOCIN®, is a medication that has been lauded for its clinical efficacy in the field of obstetrics and gynecology.
Encoded Therapeutics Reveals Approval from US FDA for IND Application and Consent from Australian Health Authorities for ETX101, a Genetic Treatment Prospect for Dravet Syndrome.
The phase II trial of mFOLFIRINOX, followed by hepatic infusion of floxuridine & dexamethasone with mFOLFIRI as first-line treatment in intrahepatic cholangiocarcinoma patients (HELIX-1), was presented at 2024 ASCO_GI on Jan 18.